Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
This article was originally published in The Tan Sheet
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
You may also be interested in...
Johnson & Johnson expects innovation and marketing to restore consumer confidence in its OTC brands and drive a market-share rebound even as its U.S. sales continue to fall, dropping nearly 25% in its latest quarter.
Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.
Johnson & Johnson will not “shortchange” its commitment to returning its recalled consumer brands to the marketplace, Chief Financial Officer Dominic Caruso says.